Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Although the revision of drug prices had a negative impact on sales of generic drugs, net sales increased due to the effects of sales promotion activities and other factors, resulting in increases in operating profit and other earnings.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥16,046 million (YoY +3.5%) |
| Operating profit | ¥972 million (YoY +63.0%) |
| Ordinary income | ¥911 million (YoY +40.9%) |
| Profit attributable to owners of the parent | ¥642 million (YoY +39.0%) |
| Net income per share | ¥75.30 |
| Equity ratio | End of the current fiscal period 40.9 / End of previous period 38.8 |
| Total assets | ¥87,471 million |
| Net assets | ¥35,751 million |
| Full-year earnings forecast | Net Sales ¥63,200 million (YoY +1.4%) / Operating profit ¥2,000 million (YoY -24.2%) / Ordinary income ¥1,400 million (YoY -40.4%) / Net income ¥1,300 million (YoY -35.4%) |
| Annual Dividend Forecast | ¥90 → ¥90（0.0%） |
| Depreciation and amortization | ¥653 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 9,451,169 Shares |
| Treasury Shares at Period-End | 914,847 Shares |
| Factors Behind Changes in Business Performance | Although the revision of drug prices had a negative impact on sales of generic drugs, net sales increased due to the effects of sales promotion activities and other factors, resulting in increases in operating profit and other earnings. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the revision of drug prices had a negative impact on sales of generic drugs, net sales increased due to the effects of sales promotion activities and other factors, and operating profit increased as a result of higher net sales.